Eltrombopag for Chemotherapy-induced Thrombocytopenia

Inclusion Criteria:

• Aged ≥18 years old, male or female;

• Conform to the diagnostic criteria of chemotherapy-induced thrombocytopenia (CIT);Ineffective after repeated treatment with rhTPO or IL-11；

• Stop radiotherapy or chemotherapy for more than 1 month;

• Platelet counts <30 ×10^9/L, and bleeding tendency;

• Estimated survival period ≥ 6 months；

• People who are willing to sign the informed consent voluntarily and follow theresearch program.

• Liver and kidney function<1.5×upper limit of normal, qualified for physicalexamination；

• Subject is practicing an acceptable method of contraception. Women of childbearingpotential must have a negative serum pregnancy test in the whole study;

Exclusion Criteria:

• Those with uncontrollable primary diseases of important organs, such as extensivemetastasis of malignant tumors, liver failure, heart failure, kidney failure andother diseases；

• Patients with poor compliance;

• Positive serology for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and/orhepatitis D virus (HDV), Syphilis; Positive for Epstein-Barr Virus DNA,Cytomegalovirus DNA;

• Accompanied by extensive and severe bleeding, such as hemoptysis, uppergastrointestinal bleeding, intracranial hemorrhage, etc.

• There is currently a heart disease requiring treatment or a poorly controlledhypertension judged by the investigator；

• Patients with thrombotic diseases such as pulmonary embolism, thrombosis, andatherosclerosis；

• Those who have received allogeneic stem cell transplantation or organtransplantation in the past；

• Patients with mental disorders who cannot normally obtain informed consent andundergo trials and follow-up；

• Patients whose toxic symptoms caused by treatment before participating in the trialhave not disappeared；

• Other serious diseases that may restrict participants from participating in thistrial (such as diabetes; severe heart failure; myocardial obstruction or unstablearrhythmia or unstable angina in the past 6 months; gastric ulcers; mobilityAutoimmune diseases, etc.)；

• Patients with sepsis or patients with other irregular bleeding；

• Patients taking antiplatelet drugs at the same time；

• Pregnant women, suspected pregnancy (a positive pregnancy test for human chorionicgonadotropin in urine at screening) and breastfeeding patients；

• Pre-existing cardiac disease, including congestive heart failure of New York HeartAssociation [NYHA] Grade III/IV, arrhythmia requiring treatment or myocardialinfarction within the last 6 months. No arrhythmia known to increase the risk ofthrombotic events (e.g. atrial fibrillation), or patients with a QT >450msec or QTc > 480 for patients with a Bundle Branch Block;

• Researchers believe that patients should not participate in the test of any othercondition.